Campbell Soup Co. vs Twist Bioscience Corp — how do they compare? Campbell Soup Co. trades at $19.18 (market cap $5.78B), while Twist Bioscience Corp trades at $159.86 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Campbell Soup Co. pays a 5.16% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Twist Bioscience Corp for 27 Days on average.
| CPB | TWST | |
|---|---|---|
Market Cap | $5.78B | $10.08B |
Volume | 11,705,427 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $205.00 |
52-Week Low | $18.90 | $25.45 |
Typical Hold Time | 98 Days | 27 Days |
Enterprise Value | $12.83B | $10.01B |
Dividend Yield | 5.16% | — |
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $18.90, down 0.53% with bearish technical signals. The company reported mixed Q2 2026 earnings, beating expectations but showing margin pressure. Recent dividend cut of 36% and workforce reduction signal turnaround efforts amid declining profitability. Valuation appears reasonable with P/E of 14.79 and P/S of 0.6, but revenue growth remains challenged.
The outlook remains cautious with analyst consensus leaning heavily toward Hold (58.62%). While cost-saving initiatives and balance sheet improvements provide some support, persistent margin compression and competitive pressures create headwinds. The stock trades near the lower end of analyst targets ($18-22), offering limited upside potential amid ongoing operational challenges.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →